Literature DB >> 27475482

Dose-volume histogram analysis of composite EQD2 dose distributions using the central shielding technique in cervical cancer radiotherapy.

Tomoaki Tamaki1, Shin-Ei Noda2, Tatsuya Ohno2, Yu Kumazaki3, Shingo Kato3, Takashi Nakano2.   

Abstract

PURPOSE: To analyze the dose-volume histogram of the central shielding technique for cervical cancer radiotherapy by computing the composite three-dimensional EQD2 dose distributions of external-beam radiotherapy plus intracavitary brachytherapy. METHODS AND MATERIALS: On a phantom, three patterns of high-risk clinical target volume (HR-CTV) with right-left diameters of 3, 4, and 5 cm were created using clinical data. Four patterns of combinations of whole-pelvis irradiation plus "pelvis irradiation using the central shielding technique" (CS) (shielding width, 3 or 4 cm) were created: 20 Gy/10 fractions + 30 Gy/15 fractions, 30 Gy/15 fractions + 20 Gy/10 fractions, 40 Gy/20 fractions + 10 Gy/5 fractions, and 50 Gy/25 fractions + 0 Gy. The intracavitary brachytherapy plan was set as 24 Gy/4 fractions prescribed to the Point A. The HR-CTV D90/D98 and modeled bladder/rectum D2cc were computed using the composite EQD2 dose distributions of all the treatment combinations.
RESULTS: If appropriate combinations of the treatment plans were selected on the basis of the CS doses and the HR-CTV sizes, the D90/D98 of HR-CTV 3 cm, HR-CTV 4 cm, and HR-CTV 5 cm were 89.7 Gy/80.6 Gy, 77.3 Gy/72.0 Gy, and 73.0 Gy/69.2 Gy in the case of CS width 3 cm, respectively; and 86.2 Gy/76.0 Gy, 73.3 Gy/67.6 Gy, and 70.9 Gy/67.1 Gy in the case of CS width 4 cm, respectively. The contributions of CS to the HR-CTV D90/bladder D2cc/rectum D2cc values were 24-56%/28-32%/9% of the CS plan doses for shielding width of 3 cm and were 13-35%/11-16%/5-6% for shielding width of 4 cm.
CONCLUSION: The dose contributions of CS were variable but not negligible when analyzing the total doses delivered to the HR-CTV.
Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central shielding technique; Cervical cancer; External-beam radiotherapy; Intracavitary brachytherapy; Whole-pelvis irradiation

Mesh:

Year:  2016        PMID: 27475482     DOI: 10.1016/j.brachy.2016.06.006

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  16 in total

1.  Plan-Optimization Method for Central-shielding Pelvic Volumetric-modulated Arc Therapy for Cervical Cancer.

Authors:  Ryuta Hirai; Tomoaki Tamaki; Mitsunobu Igari; Y U Kumazaki; Shin-Ei Noda; Shingo Kato
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Dosimetric feasibility of computed tomography-based image-guided brachytherapy in locally advanced cervical cancer: a Japanese prospective multi-institutional study.

Authors:  Yuki Otani; Tatsuya Ohno; Ken Ando; Kazutoshi Murata; Shingo Kato; Shin-Ei Noda; Keiko Murofushi; Hiroki Ushijima; Daisaku Yoshida; Noriyuki Okonogi; Fumiaki Isohashi; Masaru Wakatsuki; Takashi Nakano
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

3.  In-room computed tomography-based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study.

Authors:  Tatsuya Ohno; Shin-Ei Noda; Noriyuki Okonogi; Kazutoshi Murata; Kei Shibuya; Hiroki Kiyohara; Tomoaki Tamaki; Ken Ando; Takahiro Oike; Yu Ohkubo; Masaru Wakatsuki; Jun-Ichi Saitoh; Takashi Nakano
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

4.  Comparison of dosimetric parameters in the treatment planning of magnetic resonance imaging-based intracavitary image-guided adaptive brachytherapy with and without optimization using the central shielding technique.

Authors:  Ryo Nishikawa; Kenji Yoshida; Yasuhiko Ebina; Mayumi Omoteda; Daisuke Miyawaki; Takeaki Ishihara; Yasuo Ejima; Hiroaki Akasaka; Hitoaki Satoh; Katsusuke Kyotani; Satoru Takahashi; Ryohei Sasaki
Journal:  J Radiat Res       Date:  2018-05-01       Impact factor: 2.724

5.  Preliminary survey of 3D image-guided brachytherapy for cervical cancer at representative hospitals in Asian countries.

Authors:  Noriyuki Okonogi; Masaru Wakatsuki; Hideyuki Mizuno; Shigekazu Fukuda; Jianping Cao; Henry Kodrat; Fen Nee Lau; Miriam Joy Calaguas; Rey H de Los Reyes; Yaowalak Chansilpa; A F M Kamal Uddin; Tasbolat Adylkhanov; Chul-Koo Cho; Uranchimeg Tsegmed; Nguyen Cong Hoang; Tatsuya Ohno; Takashi Nakano; Shingo Kato
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

6.  Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer.

Authors:  Masanori Someya; Tomokazu Hasegawa; Takaaki Tsuchiya; Mio Kitagawa; Toshio Gocho; Yuuki Fukushima; Masakazu Hori; Katsutoshi Miura; Yu Takada; Kensei Nakata; Koh-Ichi Sakata
Journal:  J Radiat Res       Date:  2020-03-23       Impact factor: 2.724

7.  Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric-arc radiotherapy in cervical cancer treatment: applying the central-shielding principle to modern technology.

Authors:  Tomoaki Tamaki; Ryuta Hirai; Mitsunobu Igari; Yu Kumazaki; Shin-Ei Noda; Yoshiyuki Suzuki; Shingo Kato
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724

8.  How should we appropriately classify low-risk uterine cervical cancer patients suitable for de-intensified treatment?

Authors:  Naoya Murakami; Ikumi Kuno; Hiroshi Yoshida; Kouya Shiraishi; Tomoyasu Kato; Hiroshi Igaki
Journal:  J Radiat Res       Date:  2022-03-17       Impact factor: 2.724

9.  Patient's specific integration of OAR doses (D2 cc) from EBRT and 3D image-guided brachytherapy for cervical cancer.

Authors:  Edgar Gelover; Cabel Katherine; Christopher Mart; Wenqing Sun; Yusung Kim
Journal:  J Appl Clin Med Phys       Date:  2018-01-19       Impact factor: 2.102

10.  Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients.

Authors:  Takeaki Kusada; Takafumi Toita; Takuro Ariga; Wataru Kudaka; Hitoshi Maemoto; Wataru Makino; Kazuki Ishikawa; Joichi Heianna; Yutaka Nagai; Yoichi Aoki; Sadayuki Murayama
Journal:  Int J Clin Oncol       Date:  2020-08-27       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.